These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 32800849)

  • 1. Read-across can increase confidence in the Next Generation Risk Assessment for skin sensitisation: A case study with resorcinol.
    Gautier F; Tourneix F; Assaf Vandecasteele H; van Vliet E; Bury D; Alépée N
    Regul Toxicol Pharmacol; 2020 Nov; 117():104755. PubMed ID: 32800849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Skin sensitisation prediction using read-across, an illustrative next generation risk assessment (NGRA) case study for vanillin.
    Gautier F; Assaf Vandecasteele H; Tourneix F; van Vliet E; Alépée N; Bury D
    Regul Toxicol Pharmacol; 2023 Sep; 143():105458. PubMed ID: 37453556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a next generation risk assessment framework for the evaluation of skin sensitisation of cosmetic ingredients.
    Gilmour N; Kern PS; Alépée N; Boislève F; Bury D; Clouet E; Hirota M; Hoffmann S; Kühnl J; Lalko JF; Mewes K; Miyazawa M; Nishida H; Osmani A; Petersohn D; Sekine S; van Vliet E; Klaric M
    Regul Toxicol Pharmacol; 2020 Oct; 116():104721. PubMed ID: 32645429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Next generation risk assessment for skin sensitisation: A case study with propyl paraben.
    Assaf Vandecasteele H; Gautier F; Tourneix F; Vliet EV; Bury D; Alépée N
    Regul Toxicol Pharmacol; 2021 Jul; 123():104936. PubMed ID: 33905779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemical applicability domain of the Local Lymph Node Assay (LLNA) for skin sensitisation potency. Part 2. The biological variability of the murine Local Lymph Node Assay (LLNA) for skin sensitisation.
    Roberts DW; Api AM; Aptula AO
    Regul Toxicol Pharmacol; 2016 Oct; 80():255-9. PubMed ID: 27470439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incorporating integrated testing strategy (ITSv1) defined approach into read-across (RAx) in predicting skin sensitization potency: ITSv1-based RAx.
    Nakayama K; Zifle A; Fritz S; Fuchs A; Sakaguchi H; Miyazawa M
    Regul Toxicol Pharmacol; 2023 Mar; 139():105358. PubMed ID: 36805910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Applying a next generation risk assessment framework for skin sensitisation to inconsistent new approach methodology information.
    Gilmour N; Alépée N; Hoffmann S; Kern PS; Van Vliet E; Bury D; Miyazawa M; Nishida H; Cosmetics Europe
    ALTEX; 2023; 40(3):439-451. PubMed ID: 36919358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemical reactivity indices and mechanism-based read-across for non-animal based assessment of skin sensitisation potential.
    Roberts DW; Aptula AO; Patlewicz G; Pease C
    J Appl Toxicol; 2008 May; 28(4):443-54. PubMed ID: 17703503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Building confidence in skin sensitisation potency assessment using new approach methodologies: report of the 3rd EPAA Partners Forum, Brussels, 28th October 2019.
    Basketter D; Beken S; Bender H; Bridges J; Casati S; Corvaro M; Cuvellier S; Hubesch B; Irizar A; Jacobs MN; Kern P; Lamplmair F; Manou I; Müller BP; Roggeband R; Rossi LH
    Regul Toxicol Pharmacol; 2020 Nov; 117():104767. PubMed ID: 32866543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guiding principles for the implementation of non-animal safety assessment approaches for cosmetics: skin sensitisation.
    Goebel C; Aeby P; Ade N; Alépée N; Aptula A; Araki D; Dufour E; Gilmour N; Hibatallah J; Keller D; Kern P; Kirst A; Marrec-Fairley M; Maxwell G; Rowland J; Safford B; Schellauf F; Schepky A; Seaman C; Teichert T; Tessier N; Teissier S; Weltzien HU; Winkler P; Scheel J
    Regul Toxicol Pharmacol; 2012 Jun; 63(1):40-52. PubMed ID: 22374415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Next generation risk assessment for skin allergy: Decision making using new approach methodologies.
    Gilmour N; Reynolds J; Przybylak K; Aleksic M; Aptula N; Baltazar MT; Cubberley R; Rajagopal R; Reynolds G; Spriggs S; Thorpe C; Windebank S; Maxwell G
    Regul Toxicol Pharmacol; 2022 Jun; 131():105159. PubMed ID: 35311660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A hypothetical skin sensitisation next generation risk assessment for coumarin in cosmetic products.
    Reynolds G; Reynolds J; Gilmour N; Cubberley R; Spriggs S; Aptula A; Przybylak K; Windebank S; Maxwell G; Baltazar MT
    Regul Toxicol Pharmacol; 2021 Dec; 127():105075. PubMed ID: 34728330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expansion of the Cosmetics Europe skin sensitisation database with new substances and PPRA data.
    Hoffmann S; Alépée N; Gilmour N; Kern PS; van Vliet E; Boislève F; Bury D; Cloudet E; Klaric M; Kühnl J; Lalko JF; Mewes K; Miyazawa M; Nishida H; Tam Brami MT; Varçin M; Api AM; Europe C
    Regul Toxicol Pharmacol; 2022 Jun; 131():105169. PubMed ID: 35447229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimating skin sensitization potency from a single dose LLNA.
    Roberts DW
    Regul Toxicol Pharmacol; 2015 Apr; 71(3):437-43. PubMed ID: 25625585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 10-step framework for use of read-across (RAX) in next generation risk assessment (NGRA) for cosmetics safety assessment.
    Alexander-White C; Bury D; Cronin M; Dent M; Hack E; Hewitt NJ; Kenna G; Naciff J; Ouedraogo G; Schepky A; Mahony C; Europe C
    Regul Toxicol Pharmacol; 2022 Mar; 129():105094. PubMed ID: 34990780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assuring consumer safety without animal testing: a feasibility case study for skin sensitisation.
    Maxwell G; Aleksic M; Aptula A; Carmichael P; Fentem J; Gilmour N; Mackay C; Pease C; Pendlington R; Reynolds F; Scott D; Warner G; Westmoreland C
    Altern Lab Anim; 2008 Nov; 36(5):557-68. PubMed ID: 19025323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemical applicability domain of the local lymph node assay (LLNA) for skin sensitisation potency. Part 4. Quantitative correlation of LLNA potency with human potency.
    Roberts DW; Api AM
    Regul Toxicol Pharmacol; 2018 Jul; 96():76-84. PubMed ID: 29730445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemical applicability domain of the Local Lymph Node Assay (LLNA) for skin sensitisation potency. Part 3. Apparent discrepancies between LLNA and GPMT sensitisation potential: False positives or differences in sensitivity?
    Roberts DW; Schultz TW; Api AM
    Regul Toxicol Pharmacol; 2016 Oct; 80():260-7. PubMed ID: 27477089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Consensus of classification trees for skin sensitisation hazard prediction.
    Asturiol D; Casati S; Worth A
    Toxicol In Vitro; 2016 Oct; 36():197-209. PubMed ID: 27458072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Skin sensitisation testing in practice: Applying a stacking meta model to cosmetic ingredients.
    Tourneix F; Alépée N; Detroyer A; Eilstein J; Ez-Zoubir M; Teissier SM; Noçairi H; Piroird C; Basketter D; Del Bufalo A
    Toxicol In Vitro; 2020 Aug; 66():104831. PubMed ID: 32198056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.